News
Feb 27, 2025
"More than a century ago, Dr. Alois Alzheimer described the brain changes in a younger woman who had passed away from what we now call Alzheimer's disease,"…
Feb 15, 2025
CNBC’s Angelica Peebles talks to Alnylam CEO Yvonne Greenstreet about the new administration, what to expect in 2025 and the latest on their ATTR-Cardiomyopathy…
Feb 01, 2025
“The symptoms are sometimes vague and they often mimic other conditions like cancer, neuropathic conditions and heart disease,” says Dr. Keyur Shah.Abnormal…
Jan 23, 2025
Alnylam Pharmaceuticals, Inc., an American company at the forefront of innovation, today received the 2024 Tell Award from Ambassador Niculin Jaeger, Consul General…
Jan 12, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth…
Dec 16, 2024
EMPOWER CHANGEYour Voice Matters in Building a Rare Disease Advisory CouncilJoin the coalition of rare disease patients, experts, and advocates like you to push…
Dec 06, 2024
DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the AL Amyloidosis, historical…
Dec 06, 2024
Data presented at the 2024 American Heart Association (AHA) Scientific Sessions highlighted that early initiation and continuous use of acoramidis (Attruby;…